TY - JOUR
T1 - Inhibition of mitogenic stimulant-induced activation of thymocytes with zinc tetrakis-(N-methyl-4′-pyridyl) porphyrinato
AU - Kang, Jihee Lee
AU - Lee, Hui Su
AU - Jung, Hae Jin
AU - Kim, Hee Jae
AU - Hah, Jong Sik
AU - Castranova, Vincent
PY - 2002/12/1
Y1 - 2002/12/1
N2 - Zinc porphyrins have anti-inflammatory and anti-allergic properties. The objective of the present study was to characterize the mechanism of zinc tetrakis-(N-methyl-4′-pyridyl) porphyrinato (ZnTMPyP) immune modulation by investigating its effects on the proliferative activity during thymocyte stimulation with mitogenic factors and the molecular events mediating thymocyte proliferation. The results indicate that ZnTMPyP inhibited thymocyte proliferation stimulated with various mitogenic factors, such as concanavalin A (Con A), interleukin (IL)-1/β, and lipopolysaccharide-exposed macrophage supernatant, in a concentration-dependent manner. ZnTMPyP was also effective in preventing DNA binding activity of nuclear factor κB (NF-κB) and IL-2 production by thymocytes in response to Con A or IL-1β. Inhibition of p38 mitogen-activated protein kinase (MAPK) with SB203580 substantially inhibited Con A- or IL-1β-induced DNA binding activity of NF-κB, whereas ZnTMPyP inhibited the activation of p38 MAPK. ZnTMPyP also inhibited Con A-induced chemiluminescence and tyrosine phosphorylation by thymocytes. In conclusion, our findings suggest that the antiproliferative effect of ZnTMPyP may be mediated by effective inhibition of the production of reactive oxygen species, tyrosine phosphorylation, p38 MAPK activation, NF-κB activation, and IL-2 production during mitogenic stimulation of thymocytes.
AB - Zinc porphyrins have anti-inflammatory and anti-allergic properties. The objective of the present study was to characterize the mechanism of zinc tetrakis-(N-methyl-4′-pyridyl) porphyrinato (ZnTMPyP) immune modulation by investigating its effects on the proliferative activity during thymocyte stimulation with mitogenic factors and the molecular events mediating thymocyte proliferation. The results indicate that ZnTMPyP inhibited thymocyte proliferation stimulated with various mitogenic factors, such as concanavalin A (Con A), interleukin (IL)-1/β, and lipopolysaccharide-exposed macrophage supernatant, in a concentration-dependent manner. ZnTMPyP was also effective in preventing DNA binding activity of nuclear factor κB (NF-κB) and IL-2 production by thymocytes in response to Con A or IL-1β. Inhibition of p38 mitogen-activated protein kinase (MAPK) with SB203580 substantially inhibited Con A- or IL-1β-induced DNA binding activity of NF-κB, whereas ZnTMPyP inhibited the activation of p38 MAPK. ZnTMPyP also inhibited Con A-induced chemiluminescence and tyrosine phosphorylation by thymocytes. In conclusion, our findings suggest that the antiproliferative effect of ZnTMPyP may be mediated by effective inhibition of the production of reactive oxygen species, tyrosine phosphorylation, p38 MAPK activation, NF-κB activation, and IL-2 production during mitogenic stimulation of thymocytes.
UR - http://www.scopus.com/inward/record.url?scp=0036897416&partnerID=8YFLogxK
U2 - 10.1124/jpet.102.039123
DO - 10.1124/jpet.102.039123
M3 - Article
C2 - 12438537
AN - SCOPUS:0036897416
SN - 0022-3565
VL - 303
SP - 1138
EP - 1144
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 3
ER -